Graphite Bio snags $45m Series A

Graphite Bio, a next-generation gene editing company, has secured $45 million in Series A financing.

Graphite Bio, a next-generation gene editing company, has secured $45 million in Series A financing. Versant Ventures led the round with participation from Samsara BioCapital.

Source: Press Release